인체혈청 중 펜톡시필린의 정량을 위한 HPLC 분석법의 검증 및 단일용량 투여에 의한 약물동태
Validation of a HPLC Method for Determination of Pentoxifylline in Human Serum andIts Application to Single-dose Pharmacokinetics
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Abstract
A simple HPLC method was employed for the determination of pentoxifylline in human serum. After addition of internal standard (IS, 50 uL of 3 ug/mL chloramphenicol methanol solution) into the serum sample, the drug and IS were extracted by dichloromethane. Following a 1-min vortex-mixing and a 15-min centrifugation at 3500 rpm, the organic phase was transferred and evaporated to dryness under a vacuum. The residue was reconstituted with 120 µL of mobile phase and 50 µL was injected into C18 column with a mobile phase composed of 0.034 M phosphoric acid adjusted to pH 4 with 10 M NaOH and acetonitrile (75:25, v/v). The samples were detected using an ultraviolet detector at 273 nm. The method was simple, specific and validated with a limit of 10 ng/mL. Intra- and inter-day precision and accuracy were acceptable for all quality control samples including the lower limit of quantification. The applicability of this method was evaluated by analysis of human serum after oral administration of a single 400 mg dose to 8 healthy subjects. The pharmacokinetic parameters for pentoxifylline in human subjects were calculated using WinNonlin program. As a result, AUCt, Cmax, Tmax, and t1/2 were 962.28 ± 645.69 ng·hr/mL, 132.82 ± 42.05 ng/mL, 2.06 ± 2.68 hr and 8.74 ± 4.38 hr, respectively. Based on the results, this validated method appears to be useful for the pharmacokinetic study of pentoxifylline in humans.
참고문헌 (13)
- Accetto B, "results ofdouble-blind study versus vasodilator-nylidrin", 103, pp.864~9 (1982)
- Porter JM, "Multicentercontrolled double-blind trial with objectiveassessment of chronic occlusive arterial disease patients", 104, pp.65~72 (1982)
- Nishio T, "Effects of pentoxifyllineon cell shape,ATP content and deformability inrabbit erythrocytes under hyperosmolar conditions", 14, pp.915~20 (1982)
- Dettelbach HR, "Clinical pharmacology ofpentoxifylline with special reference to its hemorrheologiceffect for the treatment of intermittent claudication", 25, pp.8~16 (1985)
- Raz I, "Comparative pharmacokineticanalysis of novel sustained-release dosageforms of pentoxifylline in healthy subjects", pp.206~8
- Martindale, "32th edition" (1999)
- Burrows JL, "Determination of oxpentifylline and threemetabolites in plasma by automated capillary gas chromatographyusing nitrogen-sensitive detection", 423, pp.139~46
- Smith RV, "Pharmacokineticsof Orally Administered Pentoxifylline in Humans", 75, pp.47~52 (1986)
- Dennis M, "High-performanceliquid chromatographic analysis of pentoxifylline and 1- 7-dimetylxanthine in whole blood", 419, pp.368~74
- Lambert WE, "Simultaneous determination of pentoxifylline and threemetabolites in biological fluids by liquid chromatography", 35, pp.298~301 (1989)
- Rieck W, "Determination of 3 -xanthine metabolite in the plasma ofpatients with multiple disease using high-performance liquidchromatography", pp.7 5 7 5 419~27
- Jia Woei Wong, "Simplehigh-performance liquid chromatographic method fordetermination of pentoxifylline in human plasma", 716, pp.387~91 (1998)
- 식품의약품안전청, "고시 제 2002-60호"